Curated News
By: NewsRamp Editorial Staff
October 13, 2026
Leksum Inks Vienna Deal to Advance LK-ICU Trials
TLDR
- Leksum gains a strategic edge by partnering with Medical University of Vienna for LK-ICU trials, targeting a market impacting hundreds of thousands.
- Leksum's LK-ICU uses extracellular vesicles from bone marrow stromal cells to preserve diaphragm function during mechanical ventilation, advancing toward Phase I/II trials.
- Leksum's LK-ICU could improve quality of life for countless patients by preventing ICU-acquired weakness and easing weaning from mechanical ventilation.
- Leksum's LK-ICU, derived from bone marrow stromal cell vesicles, may nearly eliminate diaphragm damage from mechanical ventilation, a surprising preclinical finding.
Impact - Why it Matters
This news matters because ICU-acquired weakness and prolonged mechanical ventilation can lead to devastating muscle loss, extended hospital stays, and reduced quality of life for hundreds of thousands of patients each year. LK-ICU's potential to preserve diaphragm muscle function could revolutionize critical care by shortening weaning times and improving recovery. Moreover, Leksum's broader pipeline targeting sarcopenia, cancer cachexia, and muscle loss from GLP-1 drugs addresses a wide range of muscle-wasting conditions that currently lack effective therapies. The agreement with the Medical University of Vienna not only accelerates LK-ICU's clinical development but also strengthens the transatlantic collaboration necessary to bring innovative biologics to patients faster. As the population ages and the use of weight-loss drugs rises, therapies that protect muscle mass will become increasingly vital, making Leksum's work highly relevant to public health and the future of regenerative medicine.
Summary
Leksum LLC, an early-stage life sciences company based in Boston, Massachusetts, has signed an agreement with the Department of Anesthesia, Intensive Care Medicine and Pain Medicine at the Medical University of Vienna, with Phoenestra GmbH as a co-signatory, to conduct preparatory work leading up to Phase I/II first-in-human clinical trials for LK-ICU. LK-ICU is a biologic therapy consisting of extracellular vesicles derived from bone marrow mesenchymal stromal cells. Preclinical studies indicate that LK-ICU almost completely preserves diaphragm muscle fiber size and function during mechanical ventilation, a significant finding given that extended weaning from mechanical ventilation due to ICU-acquired weakness affects the quality of life of hundreds of thousands of patients annually in the U.S. and Europe. Leksum plans to initiate efforts under the agreement upon closing its Series A financing, with the planning phase expected to last several months. The company intends to use European clinical data to support its U.S. regulatory path. To view the full announcement, including downloadable images, bios, and more, click here.
In addition to LK-ICU, Leksum's pipeline includes therapies for skeletal muscle conditions such as sarcopenia, cancer cachexia, and muscle loss due to the use of weight-loss drugs (i.e., GLP-1s). The agreement marks a crucial step toward addressing acquired muscle myopathies, a significant unmet medical need. By leveraging the expertise of the Medical University of Vienna and the strategic support of Phoenestra GmbH, Leksum aims to advance LK-ICU into clinical trials, potentially transforming care for patients suffering from ICU-acquired weakness and other muscle-wasting conditions. The collaboration underscores the growing interest in extracellular vesicle-based therapies and highlights Leksum's commitment to developing innovative biologic treatments for muscle-related disorders.
Source Statement
This curated news summary relied on content distributed by Reportable. Read the original source here, Leksum Inks Vienna Deal to Advance LK-ICU Trials
